218 related articles for article (PubMed ID: 23620793)
1. Germline genetic variation modulates tumor progression and metastasis in a mouse model of neuroendocrine prostate carcinoma.
Patel SJ; Molinolo AA; Gutkind S; Crawford NP
PLoS One; 2013; 8(4):e61848. PubMed ID: 23620793
[TBL] [Abstract][Full Text] [Related]
2. Modifier locus mapping of a transgenic F2 mouse population identifies CCDC115 as a novel aggressive prostate cancer modifier gene in humans.
Winter JM; Curry NL; Gildea DM; Williams KA; Lee M; Hu Y; Crawford NPS
BMC Genomics; 2018 Jun; 19(1):450. PubMed ID: 29890952
[TBL] [Abstract][Full Text] [Related]
3. GNL3 and SKA3 are novel prostate cancer metastasis susceptibility genes.
Lee M; Williams KA; Hu Y; Andreas J; Patel SJ; Zhang S; Crawford NP
Clin Exp Metastasis; 2015 Dec; 32(8):769-82. PubMed ID: 26429724
[TBL] [Abstract][Full Text] [Related]
4. Mash1 expression is induced in neuroendocrine prostate cancer upon the loss of Foxa2.
Gupta A; Yu X; Case T; Paul M; Shen MM; Kaestner KH; Matusik RJ
Prostate; 2013 May; 73(6):582-9. PubMed ID: 23060003
[TBL] [Abstract][Full Text] [Related]
5. Icaritin suppresses development of neuroendocrine differentiation of prostate cancer through inhibition of IL-6/STAT3 and Aurora kinase A pathways in TRAMP mice.
Sun F; Zhang ZW; Tan EM; Lim ZLR; Li Y; Wang XC; Chua SE; Li J; Cheung E; Yong EL
Carcinogenesis; 2016 Jul; 37(7):701-711. PubMed ID: 27207661
[TBL] [Abstract][Full Text] [Related]
6. Histone demethylase PHF8 drives neuroendocrine prostate cancer progression by epigenetically upregulating FOXA2.
Liu Q; Pang J; Wang LA; Huang Z; Xu J; Yang X; Xie Q; Huang Y; Tang T; Tong D; Liu G; Wang L; Zhang D; Ma Q; Xiao H; Lan W; Qin J; Jiang J
J Pathol; 2021 Jan; 253(1):106-118. PubMed ID: 33009820
[TBL] [Abstract][Full Text] [Related]
7. Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers.
Mauri G; Jachetti E; Comuzzi B; Dugo M; Arioli I; Miotti S; Sangaletti S; Di Carlo E; Tripodo C; Colombo MP
Oncotarget; 2016 Jan; 7(4):3905-20. PubMed ID: 26700622
[TBL] [Abstract][Full Text] [Related]
8. A systems genetics approach identifies CXCL14, ITGAX, and LPCAT2 as novel aggressive prostate cancer susceptibility genes.
Williams KA; Lee M; Hu Y; Andreas J; Patel SJ; Zhang S; Chines P; Elkahloun A; Chandrasekharappa S; Gutkind JS; Molinolo AA; Crawford NP
PLoS Genet; 2014 Nov; 10(11):e1004809. PubMed ID: 25411967
[TBL] [Abstract][Full Text] [Related]
9. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice.
Williams TM; Hassan GS; Li J; Cohen AW; Medina F; Frank PG; Pestell RG; Di Vizio D; Loda M; Lisanti MP
J Biol Chem; 2005 Jul; 280(26):25134-45. PubMed ID: 15802273
[TBL] [Abstract][Full Text] [Related]
10. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model.
Hsieh CL; Xie Z; Yu J; Martin WD; Datta MW; Wu GJ; Chung LW
Prostate; 2007 May; 67(7):685-91. PubMed ID: 17342752
[TBL] [Abstract][Full Text] [Related]
11. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer.
Chiaverotti T; Couto SS; Donjacour A; Mao JH; Nagase H; Cardiff RD; Cunha GR; Balmain A
Am J Pathol; 2008 Jan; 172(1):236-46. PubMed ID: 18156212
[TBL] [Abstract][Full Text] [Related]
12. Bcl-2 accelerates multistep prostate carcinogenesis in vivo.
Bruckheimer EM; Brisbay S; Johnson DJ; Gingrich JR; Greenberg N; McDonnell TJ
Oncogene; 2000 Nov; 19(46):5251-8. PubMed ID: 11077442
[TBL] [Abstract][Full Text] [Related]
13. Raf kinase inhibitor protein (RKIP) deficiency decreases latency of tumorigenesis and increases metastasis in a murine genetic model of prostate cancer.
Escara-Wilke J; Keller JM; Ignatoski KM; Dai J; Shelley G; Mizokami A; Zhang J; Yeung ML; Yeung KC; Keller ET
Prostate; 2015 Feb; 75(3):292-302. PubMed ID: 25327941
[TBL] [Abstract][Full Text] [Related]
14. Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression.
Anzo M; Cobb LJ; Hwang DL; Mehta H; Said JW; Yakar S; LeRoith D; Cohen P
Cancer Res; 2008 May; 68(9):3342-9. PubMed ID: 18451161
[TBL] [Abstract][Full Text] [Related]
15. Systemic Ablation of
Pulliam TL; Awad D; Han JJ; Murray MM; Ackroyd JJ; Goli P; Oakhill JS; Scott JW; Ittmann MM; Frigo DE
Cells; 2022 Jun; 11(12):. PubMed ID: 35741020
[TBL] [Abstract][Full Text] [Related]
16. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
17. Mapping Complex Traits in a Diversity Outbred F1 Mouse Population Identifies Germline Modifiers of Metastasis in Human Prostate Cancer.
Winter JM; Gildea DE; Andreas JP; Gatti DM; Williams KA; Lee M; Hu Y; Zhang S; ; Mullikin JC; Wolfsberg TG; McDonnell SK; Fogarty ZC; Larson MC; French AJ; Schaid DJ; Thibodeau SN; Churchill GA; Crawford NP
Cell Syst; 2017 Jan; 4(1):31-45.e6. PubMed ID: 27916600
[TBL] [Abstract][Full Text] [Related]
18. Influenza H3N2 infection of the collaborative cross founder strains reveals highly divergent host responses and identifies a unique phenotype in CAST/EiJ mice.
Leist SR; Pilzner C; van den Brand JM; Dengler L; Geffers R; Kuiken T; Balling R; Kollmus H; Schughart K
BMC Genomics; 2016 Feb; 17():143. PubMed ID: 26921172
[TBL] [Abstract][Full Text] [Related]
19. Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.
Pu H; Collazo J; Jones E; Gayheart D; Sakamoto S; Vogt A; Mitchell B; Kyprianou N
Cancer Res; 2009 Sep; 69(18):7366-74. PubMed ID: 19738062
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy.
Wikström P; Lindahl C; Bergh A
Prostate; 2005 Feb; 62(2):148-64. PubMed ID: 15389804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
